Drug intelligence / Profile preview

AKB-9090

Development stage: Phase 1
Lead developer: Akebia Therapeutics
Modality: Small Molecules
Administration: Subcutaneous

Overview

AKB-9090 is an investigational drug developed by Akebia Therapeutics for acute care settings, with primary indications in **acute kidney injury** (AKI) and **acute respiratory distress syndrome** (ARDS). It is being evaluated as part of Akebia’s strategy to diversify its pipeline beyond chronic kidney disease, with clinical development initiated for AKI. As of October 2025, it is not approved for any indication and remains in early-stage development[1][2][3][7][8][9].

Targets

PHD1 (Prolyl hydroxylase domain-containing protein 1)

Beyond the preview

Go deeper on AKB-9090.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AKB-9090.

Explore the full profile